IDORSIA LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.9 CHF | +9.07% |
|
-3.55% | -10.12% |
| 04-26 | Idorsia Gets EU Medicines Regulator's Positive Opinion for Resistant Hypertension Treatment | MT |
| 04-11 | Swiss Market Index Falls as ECB Signals June Rate Cut | MT |
| Sales 2023 * | 126M 138M 11.05B | Sales 2024 * | 226M 247M 19.83B | Capitalization | 340M 372M 29.77B |
|---|---|---|---|---|---|
| Net income 2023 * | -407M -445M -35.65B | Net income 2024 * | -489M -535M -42.83B | EV / Sales 2023 * | 11.3 x |
| Net Debt 2023 * | 1.08B 1.18B 94.84B | Net Debt 2024 * | 1.12B 1.23B 98.26B | EV / Sales 2024 * | 6.46 x |
| P/E ratio 2023 * |
-0.92
x | P/E ratio 2024 * |
-1.09
x | Employees | 650 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 58.73% |
More Fundamentals
* Assessed data
More news
Latest transcript on Idorsia Ltd
More recommendations
More press releases
More news
| 1 day | +9.07% | ||
| 1 week | -3.55% | ||
| Current month | -32.81% | ||
| 1 month | -25.14% | ||
| 3 months | +26.25% | ||
| 6 months | +23.38% | ||
| Current year | -10.12% |
1 week
1.73
2.15
1 month
1.652.97
Current year
1.293.70
1 year
1.299.75
3 years
1.2927.08
5 years
1.2933.88
10 years
1.2933.88
| Managers | Title | Age | Since |
|---|---|---|---|
Jean-Paul Clozel
CEO | Chief Executive Officer | 69 | 31/05/17 |
André Muller
DFI | Director of Finance/CFO | 60 | 31/05/17 |
Martine Clozel
CTO | Chief Tech/Sci/R&D Officer | 68 | 31/05/17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jörn Aldag
BRD | Director/Board Member | 65 | 12/05/20 |
Peter Kellogg
BRD | Director/Board Member | 67 | 11/05/21 |
Jean-Paul Clozel
CEO | Chief Executive Officer | 69 | 31/05/17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 773 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 1.9 | +9.07% | 669,806 |
| 25/04/24 | 1.742 | -8.60% | 758,042 |
| 24/04/24 | 1.906 | -4.70% | 360,301 |
| 23/04/24 | 2 | 0.00% | 784,329 |
| 22/04/24 | 2 | +1.52% | 309,561 |
Delayed Quote Swiss Exchange, April 26, 2024 at 04:31 pm
More quotes
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Calendar
21/05/2024
- Q1 2024 Earnings Release - Q4 2023
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
1.9
CHF
Average target price
1.724
CHF
Spread / Average Target
-9.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.12% | 371M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- IDIA Stock
